secwatch.observer — SEC 8-K summary
======================================

Issuer:     CVRx, Inc. (CVRX)
CIK:        0001235912
Form:       8-K
Filed at:   2026-04-13T23:59:59+00:00
Accession:  0001104659-26-042354
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CVRx reports preliminary Q1 2026 revenue $14.7-14.8M, +20% YoY; gross margin 87%
--------------------------------------------------------------------------------

- Revenue expected $14.7-14.8M vs $12.3M in Q1 2025, ~20% growth.
- Gross margin ~87% (84% in Q1 2025); operating expenses ~$25M vs $23.7M.
- Cash and equivalents ~$72.3M at Mar 31, 2026; active implanting centers 257 (+5 vs Dec 2025).
- Medicare Advantage 30-day approval rate rose to 50% in Jan-Feb 2026 vs 44% in 2025 and 31% in 2024.
- First site activated in BENEFIT-HF trial on Mar 31; enrollment expected Q2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1235912/000110465926042354/0001104659-26-042354-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1235912/000110465926042354/tm2611335d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-042354

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer